Scilex Holding Company Announces FDA Approval For Commercial Manufacturing Of Gloperba, A Prophylactic Treatment For Gout Flares In Adults, To Launch June 10, 2024
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company has received FDA approval for the commercial manufacturing of Gloperba, a liquid oral version of colchicine for the prophylaxis of gout flares in adults. The product is set to launch on June 10, 2024. Gloperba targets a significant unmet need in the gout treatment market, which is projected to reach $2.0 billion in the U.S. by 2028. Scilex is well-positioned for the launch, leveraging its existing distribution network and experienced commercial team.
June 06, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scilex Holding Company has received FDA approval for Gloperba, a liquid oral gout treatment, with a launch date set for June 10, 2024. This positions Scilex to capture a significant share of the growing $2.0 billion U.S. gout treatment market.
The FDA approval for Gloperba and its upcoming launch positions Scilex to capture a significant share of the growing gout treatment market. The company's existing distribution network and commercial team further enhance its market potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100